ResultsIQ

ResultsIQ › Latest results › Emcure Pharmaceuticals Limited

Emcure Pharmaceuticals Limited strategy deck summary

NSE: EMCURE · BSE: 544210

Strategy deck of 19 Nov 2025, summarised by AI from the filing.

Emcure reports FY25 revenue ₹7,896 cr and 1H FY26 revenue ₹4,370 cr, with EBITDA margins up 80bp and PAT margins up 250bps+.

Key takeaways

  1. Revenue FY25 revenue ₹7,896 cr (FY24: ₹6,658 cr); 1H FY26 revenue ₹4,370 cr (1H FY25: ₹3,817 cr).
  2. Margins EBITDA margins up 80bp with base margins up 125bp+; PAT margins up 250bps+ with PAT growth of 30%+.
  3. India growth Domestic market growth back to above industry level, further boosted by in-licensing.
  4. Risk Regulatory changes, competitive pressures, technology changes, supply chain challenges, currency fluctuations.

Original filing on BSE

Emcure Pharmaceuticals Limited Q1 FY27 results

As filed: Revenue ₹2,580 cr (+23% year on year), EBITDA ₹533 cr (+28% year on year), PAT ₹292 cr (+36% year on year), EBITDA margin 20.6% (+79 bps).

The Q1 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q4 FY26: Revenue ₹2,470 cr (+17% year on year), EBITDA ₹480 cr (+19% year on year), PAT ₹244 cr (+24% year on year), EBITDA margin 19.4% (+37 bps). Score 63 of 100, In line with trend. EBITDA margin rose 37 bps year on year. Not enough history for a trend yet: scored on growth alone. Share price after the results: −2.7% in 30 days (Nifty 500: −1.5%).
  • Q3 FY26: Revenue ₹2,363 cr (+20% year on year), EBITDA ₹493 cr (+39% year on year), PAT ₹231 cr (+53% year on year), EBITDA margin 20.9% (+276 bps). Score 82 of 100, Above trend. EBITDA margin rose 276 bps year on year. Not enough history for a trend yet: scored on growth alone. Share price after the results: −6.0% in 30 days (Nifty 500: −4.1%).
  • Q2 FY26: Revenue ₹2,270 cr (+13% year on year), EBITDA ₹476 cr (+25% year on year), PAT ₹251 cr (+24% year on year), EBITDA margin 21.0% (+199 bps). Score 66 of 100, Above trend. EBITDA margin rose 199 bps year on year. Not enough history for a trend yet: scored on growth alone. Share price after the results: −1.2% in 30 days (Nifty 500: −0.2%).
  • Q1 FY26: Revenue ₹2,101 cr (+16% year on year), EBITDA ₹417 cr (+24% year on year), PAT ₹215 cr (+41% year on year), EBITDA margin 19.9% (+128 bps). Score 70 of 100, Above trend. EBITDA margin rose 128 bps year on year. Not enough history for a trend yet: scored on growth alone. Share price after the results: −3.5% in 29 days (Nifty 500: +0.7%).
  • Q4 FY25: Revenue ₹2,116 cr, EBITDA ₹403 cr, PAT ₹197 cr, EBITDA margin 19.1%. Not scored. No consolidated results for the same quarter last year to compare yet (consolidated revenue ₹2,116 cr). Scored once a year-earlier consolidated quarter exists. Share price after the results: +22.2% in 29 days (Nifty 500: +1.4%).
  • Q3 FY25: Revenue ₹1,963 cr, EBITDA ₹355 cr, PAT ₹156 cr, EBITDA margin 18.1%. Not scored. No consolidated results for the same quarter last year to compare yet (consolidated revenue ₹1,963 cr). Scored once a year-earlier consolidated quarter exists.
  • Q2 FY25: Revenue ₹2,002 cr, EBITDA ₹380 cr, PAT ₹202 cr, EBITDA margin 19.0%. Not scored. No consolidated results for the same quarter last year to compare yet (consolidated revenue ₹2,002 cr). Scored once a year-earlier consolidated quarter exists.

Past price moves after results do not indicate future moves. Not a recommendation.

Emcure Pharmaceuticals Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.